Abstract: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.

Abstract: A method may include treating pain, shock, and/or inflammatory conditions in a subject. A method may include using a therapeutically effective amount of an antibody, a lipoxygenase inhibitor, a cytochrome P-450 enzyme inhibitor, and/or an antioxidant configurable to at least partially treat pain, shock, and/or inflammatory conditions in a subject. A method of treating pain, shock, and/or inflammatory conditions in a subject may include inactivating or preventing at least one linoleic acid metabolite to treat certain conditions (e.g., pain, shock, and/or inflammation).

Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to 3-hydroxycotinine (3HC). The invention also provides compositions containing these antibodies and fragments thereof, and to their use in diagnostic and therapeutic applications for diseases involving nicotine activity (e.g., smoking and/or smokeless tobacco use).

Abstract: Improved methods for the production, selection and inhibition of catalytic antibodies are disclosed.

Abstract: The present invention concerns a chimeric polypeptide comprising several polypeptide domains, which is capable of being secreted in association with membrane vesicles and in particular exosomes. The present invention also concerns a polypeptide constituted by one of said domains for the secretion of a peptide or polypeptide of interest in association with membrane vesicles and in particular exosomes. The invention also concerns the use of polypeptides of the invention and of polynucleotides coding for said polypeptides for the production of immunogenic compositions based on exosomes or based on DNA or for screening protein interactions.

Abstract: A method of producing form-specific anti-peptide antibodies for a wild type protein and its one amino acid mutated protein using a peptide antigen, by obtaining a protein sequence of the wild type protein and its one amino acid mutated protein, selecting a continuous amino acid sequence without any internal cysteine residues that includes the one amino acid mutated sequence and wild type sequence corresponding to the mutated site at the end of the sequence to obtain a synthetic mutation peptide and a synthetic wild type peptide, conjugating the synthetic peptides to a carrier protein, and immunizing an animal to produce antibodies. Methods of detecting cancer and methods of treating cancer.

Abstract: Novel hapten-carrier conjugates are capable of inducing the production of antibodies, in vivo, that specifically bind to nicotine. These conjugates comprise a nicotine hapten conjugated to an immunogenic carrier protein. The novel conjugates preserve the chirality of nicotine in its native (S)-(?) state, and have good stability properties. The conjugates are useful in formulating vaccines for active immunization, that are used to prevent and treat nicotine addiction. The antibodies raised in response to the nicotine hapten-carrier conjugate are used for passive immunization. These antibodies are administered for prevention and treatment of nicotine addiction.

Abstract: Described are smoking cessation devices and kits for determining an advantageous time for a subject to quit smoking, and/or for extending the duration of smoking abstinence, based on serum levels of anti-nicotine antibodies, and personalized drug treatment methods, including methods and kits for the treatment and prevention of drug addiction, drug use and drug abuse, which include determining the subject's pre-vaccine levels of antibodies specific for the drug hapten at issue. Related methods are also described.

Abstract: Unglycosylated anti-amyloid antibodies maintained all the antigen recognition functions of the native glycosylated anti-amyloid antibodies but without, or with a much reduced, property of triggering Fc receptor-mediated inflammation response in the brain. Such unglycosylated antibodies can be used in a method for preventing, inhibiting, or treating a disease or disorder characterized by amyloid aggregation with a diminished risk of triggering or exacerbating neuroinflammation.

Abstract: Methods and compositions for antibody production are described herein to produce human antibodies in immunodeficient mice. Particularly mice are implanted with human fetal thymus cells or human thymus and human liver tissue and human hematopoietic cells followed by immunization with an antigen. Immunization involves exposure to any of a variety of antigens including tumor antigens, microbial antigens, viral antigens and/or cytokines and growth factor.

Abstract: The present invention provides, for example, methods for conveniently determining if a cancerous condition in a subject will be responsive to an IGF1R inhibitor. The invention includes patient selection methods and methods of treatment.

Abstract: A method of treating a pathological syndrome includes administration of an activated form of ultra-low doses of antibodies to an antigen, wherein said activated form is obtained by repeated consecutive dilution combined with external impact, and the antigen is a substance or a pharmaceutical agent exerting influence upon the mechanisms of formation of this particular pathological syndrome. Pharmaceutical agent for treating a pathological syndrome contains activated form of ultra-low doses of monoclonal, polyclonal or natural antibodies to an antigen, wherein said activated form is prepared by means of repeated consecutive dilution and external treatment, predominantly based on homeopathic technology, and said antigen is a substance or a drug acting as a direct cause of the pathological syndrome or involved in regulation of mechanisms of its formation.

Abstract: The present invention relates to modulators of the Neuregulin (NRG) family, particularly NRG1 and more particularly NRG1?, and most particularly NRG1?1. The present invention also relates to the use of such modulators to inhibit goblet cell hyperplasia and therefore also relates to the use of such modulators in the treatment or prevention of human diseases and disorders featuring pathological mucus production such as COPD, CF, chronic bronchitis and asthma.

Abstract: This invention relates to stable formulations of multiple antibodies comprising a plurality of antibodies and an effective amount of a succinate buffer wherein the pH of the formulation is between about 4.5 and about 7.0.

Abstract: The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrPSc) under native conditions and the use thereof in methods of prion disease detection, therapy and disease research in general.

Abstract: Methods and compositions are described for targeting therapeutic and diagnostic molecules to particular types of cells using targeting antibodies or other targeting moeities.

Abstract: The present invention relates to the composition and methods of use of Stat3 pathway inhibitors or cancer stem cell inhibitors in combination treatment of cancer.

Abstract: Methods of treating, preventing or managing cancers are disclosed. The methods encompass the administration of SNS-595 in combination with a second active agent. In certain embodiments, the method of treatment comprise administering SNS-595 in combination with cisplatin, carboplatin, gemcitabine or a combination thereof.

Abstract: The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of using such antibodies to diagnose and treat disease.

Abstract: This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.

Abstract: The invention concerns in one embodiment a method for treating glaucoma or elevated IOP in a patient comprising administering to the patient an effective amount of a composition comprising an agent that modulates PAI-1 binding to vitronectin. In another embodiment, the invention concerns a method of manufacturing a compound to be used as a treatment for glaucoma or elevated IOP comprising providing a candidate substance suspected of modulating PAI-1 binding, selecting the compound by assessing the ability of the candidate substance to decrease the amount of active PAI-1 in the trabecular meshwork of a subject suffering from glaucoma or elevated PAI-1, and manufacturing the selected compound.

Abstract: We have discovered that administering anti-ceramide antibody treats and prevents an array of diseases mediated by cytolytic T lymphocyte (CTLs)-induced killing and by damage to endothelial microvasculture, including radiation-induced GI syndrome, Graft vs. Host diseases, inflammatory diseases and autoimmune diseases. We have also discovered new anti-ceramide monoclonal antibodies, that have therapeutic use preferably in humanized form to treat or prevent these diseases.

Abstract: The present invention relates to a compound having the general Formula (I): wherein: m and n are each independently an integer from 1 to 6; X1-X3 and Y1-Y3 are each independently O or S; R1-R3 are each independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl; and R is (CH2)x—C(?O)NR?—(CH2)y—NR?R? whereas: x and y are each independently an integer from 1 to 6; and R? and R? are each independently selected from the group consisting of hydrogen, alkyl, and cycloalkyl; and to an antibody comprising an antigen recognition region capable of specifically binding the above compound.

Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.

Abstract: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of a patient that has Alzheimer's disease or vascular dementia, or is at risk for developing Alzheimer's disease. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody and pharmaceutical compositions comprising such antagonists.

Abstract: A nanotube device comprises a gel matrix that includes microcapsules and functionalized nanotubes, or other functionalized nanostructures incorporated into said gel matrix. Pharmaceutical compositions and methods of treatment comprising same. The pharmaceutical compositions of the present invention enable the specific and targeted delivery of therapeutic agents such as DNA molecules, peptides, including antibodies, drug molecules (e.g. small organic molecules), while offering sufficient resistance towards mucus layer of the intestine and high concentrations of enzymes and other molecules found in the blood stream and the GI tract.

Abstract: The present invention provides compounds of the formula X—R1-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5; or R1(X)-D-[Dpr, Orn or Lys](A)-R2(Z)-D-[Dpr, Orn or Lys](B)—R3(Y)—NR4R5, in which X is a hard acid cation chelator, a soft acid cation chelator or Ac-, R1, R2 and R3 are independently selected from a covalent bond or one or more D-amino acids that can be the same or different, Y is a hard acid cation chelator, a soft acid cation chelator or absent, Z is a hard acid cation chelator, a soft acid cation chelator or absent, and A and B are haptens or hard acid cation chelators and can be the same or different, and R4 and R5 are independently selected from the group consisting of hard acid cation chelators, soft acid cation chelators, enzymes, therapeutic agents, diagnostic agents and H. The present invention also provides methods of using these compounds and kits containing the compounds.

Abstract: The present invention provides pharmaceutical compositions formulated for direct delivery to the GI tract of a patient comprising an antibody specific for a target apical intestinal receptor. The present invention further provides methods of treating diseases and conditions in a patient comprising administering directly to the GI tract of the patient, compositions of the present invention wherein modulation of the target apical intestinal receptor by the antibody treats the condition.

Abstract: Unnatural substrates of prenylation enzymens and antibodies that recognize unique moieties of prenylated proteins, which unique moieties are transferred from the unnatural substrates are used for detecting and isolating prenylated proteins, and for screening for inhibitors of prenylation enzymes.

Abstract: The present invention relates to Fibroblast-Growth Factor Receptor 4 (FGRF4) inhibitors for co-administration with a therapeutic procedure or/and agent for the prevention, alleviation or/and treatment of a hyperproliferative disorder, e.g. cancer, such as chemotherapy resistant cancer. Further, the present invention relates to a diagnostic procedure wherein expression status and/or polymorphisms of the FGFR4 gene are determined in a patient suffering from a hyperproliferative disorder, e.g. cancer. Based on the results of this determination and the status of the disorder to be treated a therapeutic protocol may be developed. Yet another subject of the present invention is a screening method.

Abstract: A method of treatment of cancer, viral infections, and the like administers anti-TK1 antibody, constituted as the complete antibody or a fragment thereof. The antibody binds to the surface of cells expressing TK1 thereon. The antibody, with or without another agent bound thereto, may effect complement mediated lysis, antibody-dependent cell-mediated cell cytotoxicity, apoptosis, an immune response by the mammal, a reduction in cellular replication, a combination thereof, or the like for such cells. The antibody may be coupled to an immune response stimulator, a cytotoxin, an enzyme, a combination, or the like to effect the treatment desired.

Abstract: It is disclosed here a method for reducing phosphate absorption in a human or non-human animal subject wherein the subject consumes a diet containing phytic acid or phytate and either has or is at risk of developing hyperphosphatemia. The method includes the step of administering orally to the subject an anti-phytic acid (C6H6[OPO(OH)2]o) antibody or an anti-phytate antibody in an amount effective to reduce or maintain the serum phosphate concentration in the subject.

Abstract: Methods and compositions for modulating GABA release in a subject are provided. A preferred embodiment provides a composition containing an effective amount of an ErbB4 ligand to enhance or promote GABA release, i.e., GABAergic transmission. The ErbB4 ligand can be an agonist ligand or an antagonist ligand depending on the disorder to be treated. Methods for treating neurological disorders are also provided. Representative disorders that can be treated include, but are not limited to schizophrenia, epilepsy, depression and anxiety, insomnia, stroke, pain, bipolar, autism, or a combination thereof. By increasing GABA release a sedative effective can be induced in the subject. Methods for inducing a stimulatory effect in a subject are also provided. In these methods, an effective amount of an ErbB4 antagonist ligand is administered to the subject to reduce or inhibit GABA release in the subject.

Abstract: Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue The application relates to the use of an anti-MAdCAM antibody for the manufacture of a medicament for the treatment of coeliac disease and/or tropical sprue. Methods of treatment for coeliac disease and/or tropical sprue using a therapeutically effective amount of an anti-MAdCAM antibody are also included.

Abstract: The present invention provides methods of diagnosis, providing a prognosis and a therapeutic target for the treatment of cancers that express N-cadherin, including prostrate and bladder cancers.

Abstract: The present invention provides methods of treating a subject diagnosed with, or at risk for developing, pathogenic fibrosis, particularly pulmonary fibrosis. The method of the invention comprises administering to the subject a compound or composition which inhibits semaphorin (SEMA) 7A, SEMA 7A receptors, or downstream effectors. A SEMA 7A inhibitor comprises an antibody, a soluble SEMA 7A receptor, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, a soluble receptor, or any combinations thereof.

Abstract: The present invention relates to a method for diagnosis of a disease selected from the group of diabetes, vasculitis, collagenosis, an inflammatory rheumatic disease and arteriosclerosis wherein, presence or absence of an anti-AT1-receptor antibody is determined in a sample from a patient to be diagnosed and wherein, the presence of an anti-AT1-receptor antibody is indicative of the disease. The invention further relates to the use of an inhibitor of an anti-AT1-receptor antibody or an inhibitor of an AT1-receptor for the production of a medicament as well as plasmapheresis of blood for the removal of anti-AT1-receptor antibodies.

Abstract: This invention provides, inter alia, methods and compositions for treating, reducing the incidence of, reducing the severity of, or delaying onset or advancement, of synovitis and/or bleeding-associated inflammation in a subject in need thereof. The compositions comprise, and methods make use of, an effective amount of an agent, which abrogates or diminishes activation of the C5aR complement pathway in said subject, and optionally other therapeutic agents including a coagulation factor, other hemostatic factor, and/or second anti-inflammatory agent.

Abstract: The present invention relates to the identification of a novel role of CXCR-4 in cell transformation and aberrant cellular proliferation. In particular, the present invention relates to the altered gene expression of CXCR-4 in a number of primary tumors and cell lines derived from tumors, in addition to, the altered gene expression of ligands for CXCR-4. Further, the present invention relates, in part, to the Applicant's surprising discovery that the inhibition of CXCR-4 gene expression or the inhibition of CXCR-4 activity in transformed cells reverses the transformed phenotype.

Abstract: Compositions comprising a purified and/or isolated antibody, humanized antibodies, precipitates and anti-sera that specifically bind to or are otherwise directed against ROR1 protein. The compositions may be used for detecting ROR1 in a sample from a subject that is suspected or known to contain cancer cells. The ROR1 antibodies are especially useful in identifying and treating lymphomas and ademocarcinomas. Vaccines and related methods for protecting a subject against diseases that involve expression of ROR1 are also provided, as are human anti-sera effective in abrogating interactions between Wnt5a protein and ROR1 that contribute to the survival of certain cancer cells, such as CLL cells.

Abstract: The present invention relates to amino acid sequences that are directed G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

Abstract: The present invention relates to a novel use of alpha10, or a heterodimer thereof, for affecting cartilage extracellular matrix (ECM) turnover. Further, it relates to the use of a binding entity binding specifically to alpha10, or a heterodimer thereof, in the preparation of a medicament for treating a condition affecting ECM, such as rheumatoid arthritis and osteoarthritis. In particular, the invention relates to a method of treating an individual with a condition affecting ECM turnover, comprising administering to the individual an effective amount of a binding agent entity binding specifically to alpha10, or a heterodimer thereof.

Abstract: The present invention relates to a new use of inhibitors of leukotriene B4 receptor BLT2 for treating asthma. More particularly, the present invention relates to a pharmaceutical composition for treating asthma comprising BLT2 inhibitors and a method for treating asthma using BLT2 inhibitors. The present inventors investigated the role of BLT2 in the pathogenesis of asthma using a murine model and demonstrated that BLT2 plays a critical role in the development of AHR and airway inflammation by employing BLT2 inhibitors, such as antisense oligonucleotide. Therefore, the BLT 2 inhibitors according to the present invention can be effectively used as a therapeutic composition for treating asthma.

Abstract: The invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament utilized for the treatment of multiple sclerosis and/or rheumatoid arthritis in a subject that is preferably a primate or a human. In another embodiment, the invention relates to the use of an antibody which can specifically bind to chemokine receptor CCR2 for producing a medicament that is utilized for depleting monocytes in subjects suffering from multiple sclerosis and/or rheumatoid arthritis. The invention further relates to corresponding in vitro methods and therapeutic methods. And antibody which binds to CD 14, for example, can be used in addition to the antibody that can bind to CCR2.

Abstract: Modified annexin proteins, including heterodimers and homodimer of various human annexins, are provided for treatment of cerebral thrombosis and global cerebral ischemia. Also provided are phosphatidylserine (PS) binding proteins for treatment of cerebral thrombosis and global cerebral ischemia. The modified annexins and/or PS binding proteins bind PS on cell surfaces, thereby preventing the attachment of leukocytes and platelets to endothelial cells during post-ischemic reperfusion. By maintaining endothelial cell and vascular wall integrity PS binding proteins and/or modified annexin proteins decrease cerebral hemorrhage. Modified annexins and other PS binding proteins also suppress the production of mediators of edema, the extension of cerebral damage during reperfusion and the risk of rethrombosis. Thus, modified annexin proteins and/or other PS binding proteins decrease brain damage following cerebral thrombosis and global cerebral ischemia.

Abstract: The invention discloses high levels of receptors for Clostridium perfringens enterotoxin (CPE) have been found in ovarian cancer and uterine cancer tissue samples. In addition, successful in vivo treatment of a mouse model of ovarian cancer with intraperitoneal injection of CPE is disclosed. High levels of Ep-CAM protein is also disclosed in ovarian cancer tissue samples. Thus, the invention provides a method of treating ovarian cancer and uterine cancer by administering CPE. The invention also provides a method of treating cancer in a mammal involving intraperitoneal administration of CPE, where at least some cancerous cells are located in or adjacent to the peritoneal cavity of the mammal. The invention also provides a method of treating ovarian cancer involving administering an anti-Ep-CAM antibody. The invention also provides a method of treating cancers expressing claudin-3 or claudin-4 by administering an antibody against claudin-3 and/or an antibody against claudin-4.

Abstract: This invention is generally related to methods of forming coatings for implantable medical devices, such as drug delivery vascular stents. The methods are for forming coatings to control the release of a peptide such as RGD, and a hydrophobic drug. Both single layer and multiple layer coating constructs are encompassed in the various embodiments of the present invention.

Abstract: The present invention relates to the field of diagnosis and treatment of neurodegenerative diseases, ischemic events, and central nervous system injury, and provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. The present invention in particular relates to the discovery that the expression of Annexin II is involved in apoptosis induced by oxidative stress, and that anti-sense Annexin II RNA and Annexin II siRNA protected the cells from this apoptosis. Thus Annexin II inhibitors prevent the damage caused by said ischemic event.

Abstract: The invention provides the identification and characterization of disease and cancer-associated antigen, RAAG10. The invention also provides a family of monoclonal antibodies that bind to antigen RAAG10, methods of diagnosing and treating various human cancers and diseases that express RAAG10.

Abstract: An assay system is provided in which gossypol is used as a biological marker to detect evolved resistance of insects to Bt cotton. Detection of gossypol using a monoclonal antibody ELISA-based protocol enables at risk populations of insects to be evaluated for evolved resistance to Bt present in a genetically modified cotton. The specificity of the monoclonal antibody to gossypol also enables the production of nanoparticles having a conjugated monoclonal antibody which retains the ability to selectively bind gossypol. Accordingly, nanoparticles can be provided with additional target ligands, such as antibodies, so as to specifically attach to tumors or cancer cells thereby delivering the gossypol to the target cells.